PNP Therapeutics

The PNP Technology

Patents

Parker WB, Sorscher EJ (January 14, 2014) Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs. US patent number 8,628,767.

Ealick; Steven E., Parker; William B., Secrist, III; John A., and Sorscher; Eric J. (February 10, 2009) Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof. U.S. patent number 7,488,598.

Sorscher EJ, Bennett LL Jr, and Parker WB (December 2006) Purine nucleoside phosphorylase gene therapy for human malignancy. Japanese Patent number 3,874,420.

Ealick SE, Parker WB, Secrist JA III, and Sorscher EJ (May 2, 2006) Mutant purine nucleoside phosphorylase proteins and cellular deliver thereof. US patent number 7,037,718.

Sorscher EJ, Parker WB, Waud WR, Gadi VK, and Bennett LL Jr (Oct 25, 2005) Recombinant bacterial cells for delivery of PNP to tumor cells. US patent number 6,958,318.

Ealick SE, Parker WB, Secrist JA III, and Sorscher EJ (May 1, 2003) Mutant purine nucleoside phosphorylase proteins and cellular deliver thereof. International Publication Number WO 03/035012 A2.

Sorscher EJ, Bennett LL Jr, and Parker WB (December 18, 2002) Purine nucleoside phosphorylase gene therapy for human malignancy. European Patent number 0715523.

Sorscher EJ, Parker WB, Waud W, Gadi VK, and Bennett LL Jr (December 10, 2002) Recombinant bacterial cells for delivery of PNP to tumors cells. US Patent number 6,491,905.

Sorscher EJ, Bennett LL Jr, and Parker WB (January 25, 2000) Purine nucleoside phosphorylase gene therapy for human malignancy. US Patent number 6,017,896.

Sorscher EJ, Parker WB, and Bennett LL Jr (September 3, 1996) Purine nucleoside phosphorylase gene therapy for human malignancy. US Patent number 5,552,311.

Ealick; Steven E. (Ithaca, NY), Parker; William B. (Birmingham, AL), Secrist, III; John A. (Birmingham, AL), Sorscher; Eric J. (Birmingham, AL)